Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DURECT Corp.
Dosing complete in cohort 3, phase II study for postoperative pain relief depot
October 26th, 2005
DURECT Corp. (DRRX) announced the completion of dosing in the third and final cohort of the phase II dose-escalation study in hernia patients in Australia for DURECT's postoperative pain relief depot, SABER-Bupivacaine. The company completed enrollment of approximately 60 patients in cohort 3. SABER-Bupivacaine is based on DURECT's patented SABER delivery technology and is intended to be administered around the surgical site after surgery to provide 3 days or more of regional pain relief. The results of cohort 3 are currently being analyzed. "The completion of dosing of the third and final cohort for this phase II trial for our SABER-Bupivacaine...
Source: Elder Law Weekly (2005-10-26)
|
